CA3143604A1 - Methods for treatment of subjects with psoriatic arthritis - Google Patents
Methods for treatment of subjects with psoriatic arthritis Download PDFInfo
- Publication number
- CA3143604A1 CA3143604A1 CA3143604A CA3143604A CA3143604A1 CA 3143604 A1 CA3143604 A1 CA 3143604A1 CA 3143604 A CA3143604 A CA 3143604A CA 3143604 A CA3143604 A CA 3143604A CA 3143604 A1 CA3143604 A1 CA 3143604A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- week
- dose
- patient
- tildrakizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921015050 | 2019-04-15 | ||
| IN201921015050 | 2019-04-15 | ||
| IN202021004422 | 2020-01-31 | ||
| IN202021004422 | 2020-01-31 | ||
| PCT/IB2020/053565 WO2020212874A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3143604A1 true CA3143604A1 (en) | 2020-10-22 |
Family
ID=72837755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3143604A Pending CA3143604A1 (en) | 2019-04-15 | 2020-04-15 | Methods for treatment of subjects with psoriatic arthritis |
Country Status (16)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025036280A1 (zh) * | 2023-08-11 | 2025-02-20 | 信达生物制药(苏州)有限公司 | 既往接受生物制剂治疗斑块状银屑病的受试者转用抗IL23p19抗体治疗斑块状银屑病的方法 |
| TW202511290A (zh) * | 2023-09-07 | 2025-03-16 | 大陸商信達生物製藥（蘇州）有限公司 | 一種重組抗ＩＬ－２３ｐ１９抗體治療中重度銀屑病的方法 |
| WO2026069253A1 (en) * | 2024-09-30 | 2026-04-02 | Sun Pharmaceutical Industries Limited | Long term safety of tildrakizumab in psoriatic arthritis |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7807389B2 (en) * | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| WO2008063213A2 (en) * | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| HUE042172T2 (hu) * | 2007-02-23 | 2019-06-28 | Merck Sharp & Dohme | Genetikailag elõállított anti-il-23P19 antitestek |
| WO2010027766A1 (en) * | 2008-08-27 | 2010-03-11 | Schering Corporation | Lyophilized formulatons of engineered anti-il-23p19 antibodies |
| KR102049223B1 (ko) * | 2010-11-04 | 2019-11-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 항－ｉｌ－２３ 항체 |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
-
2020
- 2020-04-15 MX MX2021012652A patent/MX2021012652A/es unknown
- 2020-04-15 CA CA3143604A patent/CA3143604A1/en active Pending
- 2020-04-15 BR BR112021020612A patent/BR112021020612A2/pt unknown
- 2020-04-15 AU AU2020259375A patent/AU2020259375A1/en active Pending
- 2020-04-15 MY MYPI2021005910A patent/MY210310A/en unknown
- 2020-04-15 JP JP2021561000A patent/JP7628962B2/ja active Active
- 2020-04-15 KR KR1020217037137A patent/KR20210140780A/ko active Pending
- 2020-04-15 SG SG11202111056YA patent/SG11202111056YA/en unknown
- 2020-04-15 CN CN202080029205.6A patent/CN113825768A/zh active Pending
- 2020-04-15 WO PCT/IB2020/053565 patent/WO2020212874A1/en not_active Ceased
- 2020-04-15 PH PH1/2021/552536A patent/PH12021552536A1/en unknown
- 2020-04-15 US US17/603,921 patent/US20220298233A1/en active Pending
- 2020-04-15 EP EP20790874.0A patent/EP3956357A4/en active Pending
- 2020-04-15 MA MA055729A patent/MA55729A/fr unknown
-
2021
- 2021-10-12 IL IL287213A patent/IL287213A/en unknown
- 2021-10-14 JO JOP/2021/0279A patent/JOP20210279A1/ar unknown
-
2025
- 2025-01-30 JP JP2025013906A patent/JP2025069284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020259375A1 (en) | 2021-10-28 |
| MX2021012652A (es) | 2022-01-24 |
| EP3956357A4 (en) | 2023-01-04 |
| MY210310A (en) | 2025-09-10 |
| JP7628962B2 (ja) | 2025-02-12 |
| EP3956357A1 (en) | 2022-02-23 |
| SG11202111056YA (en) | 2021-11-29 |
| CN113825768A (zh) | 2021-12-21 |
| US20220298233A1 (en) | 2022-09-22 |
| BR112021020612A2 (pt) | 2021-12-28 |
| PH12021552536A1 (en) | 2022-07-04 |
| MA55729A (fr) | 2022-02-23 |
| JOP20210279A1 (ar) | 2021-10-14 |
| WO2020212874A1 (en) | 2020-10-22 |
| KR20210140780A (ko) | 2021-11-23 |
| JP2022529266A (ja) | 2022-06-20 |
| JP2025069284A (ja) | 2025-04-30 |
| IL287213A (en) | 2021-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240376210A1 (en) | Vedolizumab for the treatment of fistulizing crohn's disease | |
| JP2025069284A (ja) | 乾癬性関節炎に罹患している対象者の治療方法 | |
| JP7357646B2 (ja) | 乾癬の治療のための組成物及び方法 | |
| US20260035472A1 (en) | Methods for the treatment of thyroid eye disease | |
| JP2017521427A (ja) | 改善されたＡβプロトフィブリル結合抗体 | |
| RU2697383C2 (ru) | Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом | |
| US20240059783A1 (en) | Anti-ox40 antagonistic antibodies and dosage for the treatment of ox40-mediated disorders | |
| AU2023211042A9 (en) | Methods for treatment of subjects with plaque psoriasis of the scalp | |
| US20250011417A1 (en) | Methods for the treatment of thyroid eye disease | |
| JP2026062653A (ja) | シェーグレン症候群の処置 | |
| US20250263476A1 (en) | Dosage regimens for treating multifocal motor neuropathy (mmn) | |
| US10736961B2 (en) | Method of averting opioid addiction | |
| EA053193B1 (ru) | Способы лечения субъектов с псориатическим артритом | |
| RU2852738C1 (ru) | Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17) | |
| WO2025146509A1 (en) | Methods of treating multifocal motor neuropathy (mmn) | |
| HK40117117A (en) | Dosage regimens for treating multifocal motor neuropathy (mmn) | |
| JP2026501785A (ja) | 自己免疫疾患の治療のための抗ｃｄ３８抗体 | |
| WO2025106642A1 (en) | Methods for the treatment of thyroid eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240412 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250226 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250226 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250320 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250411 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250411 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250822 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250822 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250822 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250910 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260128 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260128 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260128 |